SCHEMBL1027011

SCHEMBL1027011

CC(C)n1cnc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.68
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
HSD17B10 Q99714 1/20 0.68
HCAR3 P49019 1/20 0.51
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 3/20 0.50
TP53 P04637 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
KDM4E B2RXH2 4/20 0.48
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HTT P42858 2/20 0.47
GFER P55789 1/20 0.47
APAF1 O14727 1/20 0.46
HDAC8 Q9BY41 1/20 0.44
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL10432863 0.98 HPGD (0.66) HPGDMEN1KMT2AHSD17B10HCAR3
Hydrochloric Acid SCHEMBL9787788 0.98 HPGD (0.66) HPGDMEN1KMT2AHSD17B10HCAR3
SCHEMBL2146965 0.88 MEN1 (0.68) HPGDMEN1KMT2AHSD17B10HCAR3
SCHEMBL4233005 0.86 MEN1 (0.66) HPGDMEN1KMT2AHSD17B10RAB9A
SCHEMBL24942737 0.84 MEN1 (0.64) HPGDMEN1KMT2AHSD17B10RAB9A
SCHEMBL250816 0.84 MEN1 (0.64) HPGDMEN1KMT2AHSD17B10HCAR3
SCHEMBL630931 0.84 MEN1 (0.64) HPGDMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL9675201 0.84 MEN1 (0.64) HPGDMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL14638103 0.84 MEN1 (0.64) HPGDMEN1KMT2AHSD17B10HCAR3
SCHEMBL9674221 0.81 KMT2A (0.60) HPGDMEN1KMT2AHSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606290-A Method for efficiently catalyzing and synthesizing fluorine-containing polypeptide condensing agent by adopting green acid binding agent 浙江大学 2023-08-18 CN claimed
CN-116075510-A 1H-benzo [ d ] imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis 百时美施贵宝公司 2023-05-05 CN claimed
EP-0274226-B1 PROCESS FOR THE PRODUCTION OF GLYCEROL FROM FORMALDEHYDE BP Chemicals Limited (GB) 1991-03-13 EP claimed
WO-2026107422-A1 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 WO disclosed
US-20260078114-A1 COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF TYK MEDICINES INC (CN) 2026-03-19 US disclosed
US-20260015339-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY UNIVERSITE GRENOBLE ALPES (FR) 2026-01-15 US disclosed
EP-4655285-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY Université Grenoble Alpes (FR) 2025-12-03 EP disclosed
US-12378232-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2025-08-05 US disclosed
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) 2025-04-17 US disclosed
WO-2024156819-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY UNIVERSITE GRENOBLE ALPES (FR) 2024-08-02 WO disclosed
EP-4406939-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY Université Grenoble Alpes (FR) 2024-07-31 EP disclosed
US-5017579-A Use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure SANOFI (FR) 1991-05-21 US disclosed
US-4994474-A Hypotensive agents SANOFI (FR) 1991-02-19 US disclosed
EP-0398358-A2 Aluminum electroplating method MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1990-11-22 EP disclosed
US-4957925-A HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS, TREATMENT OF ANGINA SANOFI (FR) 1990-09-18 US disclosed
EP-0302793-A2 Aralkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same ELF SANOFI (FR) 1989-02-08 EP disclosed
US-4620871-A SALTS OF PHTHALAZINES AND BENZIMIDAZOLES ESZAKMAGYARORSZAGIVEGYIMUVEK (HU) 1986-11-04 US disclosed
US-4460709-A Process for producing oxygen-containing organic compounds AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1984-07-17 US disclosed
US-4160829-A ANTIBIOTICS GIST-BROCADES N.V. (NL) 1979-07-10 US disclosed
US-4151280-A ANTIALLERGENS ROUSSEL UCLAF (FR) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015339-A1 CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY CBR1, CYP4X1, CBR3 HPGD 2789/4885MEN1 4555/4885KMT2A 3594/4885
US-20260078114-A1 COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF CDK4, CDK1, CDK3 HPGD 1875/4885MEN1 2188/4885KMT2A 1465/4885
US-12378232-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK HPGD 2192/4885MEN1 1447/4885KMT2A 758/4885
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SGK1, HYPK, PCK1 HPGD 418/4885MEN1 2249/4885KMT2A 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.